Your browser doesn't support javascript.
loading
Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma.
Ung, Caitlin; Tsoli, Maria; Liu, Jie; Cassano, Domenico; Pocoví-Martínez, Salvador; Upton, Dannielle H; Ehteda, Anahid; Mansfeld, Friederike M; Failes, Timothy W; Farfalla, Annafranca; Katsinas, Christopher; Kavallaris, Maria; Arndt, Greg M; Vittorio, Orazio; Cirillo, Giuseppe; Voliani, Valerio; Ziegler, David S.
Afiliación
  • Ung C; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, High Street, Randwick, NSW 2052, Australia.
  • Tsoli M; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, High Street, Randwick, NSW 2052, Australia.
  • Liu J; School of Women's and Children's Health, University of New South Wales, Kensington, NSW 2052, Australia.
  • Cassano D; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, High Street, Randwick, NSW 2052, Australia.
  • Pocoví-Martínez S; Center for Nanotechnology Innovation, Istituto Italiano di Tecnologia, Piazza San Silvestro 12, 56127 Pisa, Italy.
  • Upton DH; Center for Nanotechnology Innovation, Istituto Italiano di Tecnologia, Piazza San Silvestro 12, 56127 Pisa, Italy.
  • Ehteda A; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, High Street, Randwick, NSW 2052, Australia.
  • Mansfeld FM; School of Women's and Children's Health, University of New South Wales, Kensington, NSW 2052, Australia.
  • Failes TW; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, High Street, Randwick, NSW 2052, Australia.
  • Farfalla A; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, High Street, Randwick, NSW 2052, Australia.
  • Katsinas C; School of Women's and Children's Health, University of New South Wales, Kensington, NSW 2052, Australia.
  • Kavallaris M; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Australian Centre for NanoMedicine, University of New South Wales, Kensington, NSW 2052, Australia.
  • Arndt GM; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Royal Parade, Parkville, VIC 3052, Australia.
  • Vittorio O; ACRF Drug Discovery Centre, Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, High Street, Randwick, NSW 2052, Australia.
  • Cirillo G; Department of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.
  • Voliani V; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, High Street, Randwick, NSW 2052, Australia.
  • Ziegler DS; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, High Street, Randwick, NSW 2052, Australia.
Cancers (Basel) ; 13(6)2021 Mar 13.
Article en En | MEDLINE | ID: mdl-33805713
ABSTRACT
Diffuse Intrinsic Pontine Gliomas (DIPGs) are highly aggressive paediatric brain tumours. Currently, irradiation is the only standard treatment, but is palliative in nature and most patients die within 12 months of diagnosis. Novel therapeutic approaches are urgently needed for the treatment of this devastating disease. We have developed non-persistent gold nano-architectures (NAs) functionalised with human serum albumin (HSA) for the delivery of doxorubicin. Doxorubicin has been previously reported to be cytotoxic in DIPG cells. In this study, we have preclinically evaluated the cytotoxic efficacy of doxorubicin delivered through gold nanoarchitectures (NAs-HSA-Dox). We found that DIPG neurospheres were equally sensitive to doxorubicin and doxorubicin-loaded NAs. Colony formation assays demonstrated greater potency of NAs-HSA-Dox on colony formation compared to doxorubicin. Western blot analysis indicated increased apoptotic markers cleaved Parp, cleaved caspase 3 and phosphorylated H2AX in NAs-HSA-Dox treated DIPG neurospheres. Live cell content and confocal imaging demonstrated significantly higher uptake of NAs-HSA-Dox into DIPG neurospheres compared to doxorubicin alone. Despite the potency of the NAs in vitro, treatment of an orthotopic model of DIPG showed no antitumour effect. This disparate outcome may be due to the integrity of the blood-brain barrier and highlights the need to develop therapies to enhance penetration of drugs into DIPG.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Australia